These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7924211)

  • 21. Lomefloxacin, a new difluoroquinolone: in vitro activity against gram-positive and gram-negative bacteria.
    Hoban D; Grabowski M; Koss J; Weselowski V
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):77S-82S. PubMed ID: 2791502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral ciprofloxacin, ofloxacin, and lomefloxacin as alternatives to intravenous antimicrobial therapy.
    Belliveau P; Nightingale CH; Quintiliani R; Crowe H; Gousee G
    Conn Med; 1993 Aug; 57(8):539-45. PubMed ID: 8243083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.
    Sahm DF; Critchley IA; Kelly LJ; Karlowsky JA; Mayfield DC; Thornsberry C; Mauriz YR; Kahn J
    Antimicrob Agents Chemother; 2001 Jan; 45(1):267-74. PubMed ID: 11120976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci.
    Korten V; Tomayko JF; Murray BE
    Antimicrob Agents Chemother; 1994 Mar; 38(3):611-5. PubMed ID: 8203863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
    Jones RN; Barrett MS; Erwin ME; Briggs BM; Johnson DM
    Diagn Microbiol Infect Dis; 1991; 14(4):319-30. PubMed ID: 1909615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.
    Barrett MS; Jones RN; Erwin ME; Johnson DM; Briggs BM
    Diagn Microbiol Infect Dis; 1991; 14(5):389-401. PubMed ID: 1665774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Activities of antimicrobial agents against 8,474 clinical isolates obtained from 37 medical institutions during 2000 in Japan].
    Yamaguchi K; Ohno A; Kashitani F; Iwata M; Kanda M; Tsujio Y; Sugiyama T; Toyoshima S; Kato J; Watanabe N; Kaku M; Kanemitsu K; Kunishima H; Kawaguchi H; Okada J; Shimoyama N; Igari J; Oguri T; Kaimori M; Watanabe K; Kobayashi Y; Uchida H; Katayama Y; Sugimoto K; Tashiro H; Kanno H; Yasujima M; Itoh K; Suwabe A; Obata R; Okada M; Kobayashi S; Tsuzimura M; Itoh A; Sumitomo M; Taminato T; Negayama K; Baba H; Makino H; Murase M; Miyamoto H; Minakuchi K; Ishigo S; Takii M; Horii T; Ono J; Takata T; Yamanaka K; Hamazaki N; Tsutsui T; Okabe H; Tatewaki K; Moro K; Hiramatsu K; Saikawa T; Ichiyama S; Nagasawa Z; Aoki Y; Matsushima T; Niki Y; Hirakata Y; Kohno S; Kuwabara M; Nakagawa K; Kageoka T; Hongo T; Yamane N
    Jpn J Antibiot; 2003 Oct; 56(5):341-64. PubMed ID: 14692376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial activity of a new antipseudomonal dual-action drug, Ro 25-0534.
    Jones RN; Sanchez ML
    Diagn Microbiol Infect Dis; 1994 Jan; 18(1):61-8. PubMed ID: 8026159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lomefloxacin, a new fluoroquinolone. Studies on in vitro antimicrobial spectrum, potency, and development of resistance.
    Aldridge KE; Henderberg A; Gebbia K; Schiro DD; Janney A; Sanders CV
    Diagn Microbiol Infect Dis; 1989; 12(3):221-33. PubMed ID: 2791485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison.
    Duggirala A; Joseph J; Sharma S; Nutheti R; Garg P; Das T
    Indian J Ophthalmol; 2007; 55(1):15-9. PubMed ID: 17189881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci.
    Jones RN; Pfaller MA; Stilwell M;
    Diagn Microbiol Infect Dis; 2001 Feb; 39(2):133-5. PubMed ID: 11248528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-vitro activity of four new fluoroquinolones.
    García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
    J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
    Noviello S; Ianniello F; Leone S; Esposito S
    Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of temafloxacin, a new difluoro quinolone antimicrobial agent.
    Chin NX; Figueredo VM; Novelli A; Neu HC
    Eur J Clin Microbiol Infect Dis; 1988 Feb; 7(1):58-63. PubMed ID: 3132380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990.
    Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT
    J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines.
    Gerlach EH; Jones RN; Allen SD; Koontz FP; Murray PR; Pfaller MA; Washington JA; Erwin ME
    Diagn Microbiol Infect Dis; 1992 Aug; 15(6):537-43. PubMed ID: 1424507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.